1. Background {#sec0005}
=============

*Middle East Respiratory Syndrome coronavirus* (*MERS-CoV; Family Coronaviridae*) may cause severe lower respiratory tract infection in humans [@bib0005], [@bib0010]. Camels are considered the likely animal source for zoonotic infection; sporadic human-to-human transmission does occur, but is considered to be inefficient based on currently available data [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050]. Until recently, new *MERS-CoV* infections in humans were reported at a steady low rate reaching ∼200 confirmed human cases early 2014. In March and April 2014, however, a surge of *MERS-CoV* infections occurred mainly in hospitals around Jeddah, Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE). This increased case load was in part attributed to an increase in community cases, but mostly to transmission within hospitals, with no evidence for evolution of a *MERS-CoV* variant with more efficient human-to-human transmission capabilities (WHO;[http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua](http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf%3Fua){#intr0255} [=](http://=){#intr0260} [1](http://1){#intr0265}). The ongoing occurrence of new cases, however, and the finding that *MERS-CoV* is endemic in dromedary camels in a wide geographic region [@bib0015], [@bib0050], [@bib0055], stresses the need for surveillance of strain diversity, to help unravel the epidemiology of this newly identified pathogen, and to provide a reference for studies into *MERS-CoV* evolution.

All currently sequenced human and camel *MERS-CoV* genomes share \>99% nucleotide identity across the ∼30 kb genome. Phylogenetic analysis has occurred mainly by analysing full-length genomes or multiple concatenated genome fragments, to provide reliable phylogenetic information [@bib0025], [@bib0060], [@bib0065], [@bib0070]. However, full length genome sequencing capacity is not widely available, and requires relatively high viral load, leading to limited success when trying to sequence animal or human samples [@bib0025].

2. Objectives {#sec0010}
=============

An accurate typing of *MERS-CoV* variants, preferably with a simple assay encompassing a short region of the *MERS-CoV* genome, is crucial in monitoring the *MERS-CoV* outbreak in real time with relatively little investments on location. In this study, we describe the development of a *MERS-CoV* variant typing assay, which can be used in monitoring *MERS-CoV* circulation, especially when more information on virus type is required rapidly from a large number of viruses from animals/humans.

3. Study design {#sec0015}
===============

3.1. In silico analysis {#sec0020}
-----------------------

Full or near full-length *MERS-CoV* genomes encompassing nucleotides 215--29770 (numbering corresponding to *MERS-CoV* EMC genome [JX869059](ncbi-n:JX869059){#intr0270}) were aligned with MAFFT version 7 (<http://mafft.cbrc.jp/alignment/server/>) ([Table 1](#tbl0005){ref-type="table"} ). To remove the redundancy from the dataset, FastGroupII analysis (<http://fastgroup.sdsu.edu/fg_tools.htm>) was performed grouping all currently available viral genomes based on nucleotide composition, resulting in 15 groups ([Table 1](#tbl0005){ref-type="table"}). One viral genome from each group was taken as representative in subsequent analyses. A summary of nucleotide positions that vary across the genomes was created using BioEdit v7.2.0 [@bib0075] and the number of nucleotide positions with variations was plotted over 1000 nucleotide windows. PhyML trees were generated using Seaview 4 software with the approximate likelihood ratio test based on a Shimodaira--Hasegawa-like procedure which used general time reversible as substitution model. Nearest neighbor interchange, subtree pruning, and regrafting-based tree search algorithms were used to estimate tree topologies, as described previously [@bib0025].Table 1Viral genomes used in this study.Group nameSequencesAccession numberRIYADH_9\_2013RIYADH_9\_2013[KJ156869](ncbi-n:KJ156869){#intr0010}RIYADH_2\_2012[KF600652](ncbi-n:KF600652){#intr0015}AL-HASA_15_2013AL-HASA_19_2013[KF600632](ncbi-n:KF600632){#intr0020}BURAIDAH_1\_2013[KF600630](ncbi-n:KF600630){#intr0025}AL-HASA_2\_2013[KF186566](ncbi-n:KF186566){#intr0030}AL-HASA_21_2013[KF600634](ncbi-n:KF600634){#intr0035}AL-HASA_25_2013[KJ156866](ncbi-n:KJ156866){#intr0040}AL-HASA_17_2013[KF600647](ncbi-n:KF600647){#intr0045}AL-HASA_15_2013[KF600645](ncbi-n:KF600645){#intr0050}AL-HASA_16_2013[KF600644](ncbi-n:KF600644){#intr0055}AL-HASA_12_2013[KF600627](ncbi-n:KF600627){#intr0060}AL-HASA_3\_2013[KF186565](ncbi-n:KF186565){#intr0065}AL-HASA_4\_2013[KF186564](ncbi-n:KF186564){#intr0070}AL-HASA_18_2013[KF600651](ncbi-n:KF600651){#intr0075}AL-HASA_1\_2013[KF186567](ncbi-n:KF186567){#intr0080}AL-HASA_15_2013[KF600645](ncbi-n:KF600645){#intr0085}FRA/UAE_2012KFU_HKU1_2013[KJ650297](ncbi-n:KJ650297){#intr0090}KFU_HKU19DAM2013[KJ650296](ncbi-n:KJ650296){#intr0095}KFU_HKU13_2013[KJ650295](ncbi-n:KJ650295){#intr0100}FRA/UAE_2012[KF745068](ncbi-n:KF745068){#intr0105}HAFR-AL-BATIN_6\_2013HAFR-AL-BATIN_6\_2013[KJ156874](ncbi-n:KJ156874){#intr0110}HAFR-AL-BATIN_2\_2013[KJ156910](ncbi-n:KJ156910){#intr0115}HAFR-AL-BATIN_1\_2013[KF600628](ncbi-n:KF600628){#intr0120}RIYADH_5\_2013RIYADH_5\_2013[KJ156944](ncbi-n:KJ156944){#intr0125}RIYADH_4\_2013[KJ156952](ncbi-n:KJ156952){#intr0130}TAIF_1\_2013[KJ156949](ncbi-n:KJ156949){#intr0135}JEDDAH_1\_2013[KJ556336](ncbi-n:KJ556336){#intr0140}WADI-AD-DAWASIR_1\_2013[KJ156881](ncbi-n:KJ156881){#intr0145}QATAR_3\_2013QATAR_3\_2013[KF961221](ncbi-n:KF961221){#intr0150}QATAR_4\_2013[KF961222](ncbi-n:KF961222){#intr0155}RIYADH_1\_2012RIYADH_1\_2012[KF600612](ncbi-n:KF600612){#intr0160}BISHA_1\_2012[KF600620](ncbi-n:KF600620){#intr0165}RIYADH_3\_2013RIYADH_3\_2013[KF600613](ncbi-n:KF600613){#intr0170}Egypt_Camel_NRCE-HKU205_2014Egypt_Camel_NRCE-HKU205_2014[KJ477102](ncbi-n:KJ477102){#intr0175}ENGLAND/QATAR_2012ENGLAND/QATAR_2012[KC667074](ncbi-n:KC667074){#intr0180}EMC_2012EMC_2012[JX869059](ncbi-n:JX869059){#intr0185}RIYADH_14_2013RIYADH_14_2013[KJ156934](ncbi-n:KJ156934){#intr0190}Munich/AbuDhabi_2013Munich/AbuDhabi_2013[KF192507](ncbi-n:KF192507){#intr0195}Qatar_Camel_2\_2014Qatar_Camel_2\_2014[KJ650098](ncbi-n:KJ650098){#intr0200}JORDAN/N3_2012JORDAN/N3_2012[KC776174](ncbi-n:KC776174){#intr0205}Not in variant analysisKSA_CAMEL_363_2013[KJ713298](ncbi-n:KJ713298){#intr0210}KSA_CAMEL_376_2013[KJ713299](ncbi-n:KJ713299){#intr0215}KSA_Camel_378_2013[KJ713296](ncbi-n:KJ713296){#intr0220}KSA_CAMEL_503_2013[KJ713297](ncbi-n:KJ713297){#intr0225}KSA_CAMEL_505_2013[KJ713295](ncbi-n:KJ713295){#intr0230}Jeddah_Camel_1\_2013[KF917527](ncbi-n:KF917527){#intr0235}Jeddah_Human_1\_2013[KF958702](ncbi-n:KF958702){#intr0240}Florida/USA_2\_Saudi Arabia_2014[KJ829365](ncbi-n:KJ829365){#intr0245}Indiana/USA-1_Saudi Arabia_2014[KJ813439](ncbi-n:KJ813439){#intr0250}

3.2. *MERS-CoV* typing RT-PCR {#sec0025}
-----------------------------

Total nucleic acids were isolated using an automated MagNAPure 96 extraction with the total nucleic acid isolation kit (Roche, Mannheim, Germany) as described previously [@bib0065]. The partial S2 domain of *MERS-CoV* spike (corresponding to nucleotides 23781--24395 of *MERS-CoV* EMC genome [JX869059](ncbi-n:JX869059){#intr0285}) was amplified with the OneStep RT-PCR Kit (Qiagen) using 1x QIAGEN OneStep RT-PCR Buffer, 400 μM of each dNTP, 2 μl QIAGEN OneStep RT-PCR Enzyme Mix and 0.6 μM of primers VS804 (5′-TCAGGTTGATCAACTTAATAGT-3′) and VS805 (5′-TTGAGTAATGCCAACACCGTT-3′) in a volume of 25 μl; 30 min 50 °C, 15 min 95 °C, 40 cycles of 0.5 min 94 °C, 0.5 min 50 °C, 1 min 72 °C, and a final extension of 10 min 72 °C. A nested PCR was performed using 1x PCR Buffer, 2 mM MgCl2, 200 μM of each dNTP, 20 μM primers VS804 and VS805 and 2.5 units HotStarTaq DNA polymerase (Qiagen) in a volume of 50 μl; 15 min 95 °C, 40 cycles of 0.5 min 94 °C, 0.5 min 50 °C, 1 min 72 °C, and a final extension of 10 min 72 °C. Amplicons were sequenced directly on both strands with the BigDye Terminator version 3.1 cycle sequencing kit on an ABI PRISM 3100 genetic analyser (Applied Biosystems).

3.3. Samples {#sec0030}
------------

The detection limit of the assay was determined on RNA isolated from 10x dilutions of cell culture derived *MERS-CoV* EMC_2012 ([JX869059](ncbi-n:JX869059){#intr0290}), as described above. Virus stocks were prepared as described previously [@bib0080]. RNA was isolated from serial 10-fold dilutions of *MERS-CoV* EMC_2012 [@bib0065]. Serial 10-fold dilutions of this RNA were amplified in parallel with the *MERS-CoV* variant typing assay described above and the upE and N gene real time PCR assays [@bib0085], [@bib0090]. The sensitivity of the *MERS-CoV* variant typing assay was expressed as cycle threshold value based on the upE real time PCR assay.

On May 13 and 15, 2014, the first two *MERS-CoV* infected patients in the Netherlands who became infected upon travel to Saudi Arabia were reported to WHO; throat swabs from these patients were available [@bib0095].

In February and April 2014, nasal swabs were taken from dromedary camels of different age and sex from a slaughterhouse in Doha, Qatar [@bib0065], which were available for this study.

4. Results {#sec0035}
==========

To identify genome regions for reliable phylogenetic analysis comparable to that of full-length genome, (near) full-length *MERS-CoV* genomes ([Table 1](#tbl0005){ref-type="table"}) were aligned. Viral genomes that were 99.9% identical were grouped and one viral genome from each group was taken as representative in the analysis ([Table 1](#tbl0005){ref-type="table"}) and a PhyML tree was generated ([Fig. 1](#fig0005){ref-type="fig"} A). Four major *MERS-CoV* clusters can be discerned, represented by *MERS-CoV* Qatar_3\_2014, England/Qatar_2012, EMC_2012, and Egypt_Camel_NRCE-HKU205_2014 ([KF961221](ncbi-n:KF961221){#intr0295}, [KC667074](ncbi-n:KC667074){#intr0300}, [JX869059](ncbi-n:JX869059){#intr0305}, [KJ477102](ncbi-n:KJ477102){#intr0310}), which have been identified previously in analyses based on full-length genomes or concatenated genome fragments [@bib0025], [@bib0060], [@bib0065], [@bib0070]. The number of single nucleotide polymorphisms (SNPs) across the 15 representative *MERS-CoV* genomes was plotted over 1000 nt windows ([Fig. 1](#fig0005){ref-type="fig"}B). Four genome fragments, two located in ORF1a, one in S and one in ORF4b, showed a relatively high number of SNPs ([Fig. 1](#fig0005){ref-type="fig"}B) and for this reason already had been used as concatenated genome fragment for phylogenetic analysis [@bib0060]. However, phylogenetic trees created for these four fragments separately did not accurately reflect the phylogenetic positions of the currently known full-length *MERS-CoV* genomes (data not shown).Fig. 1Characterization of *MERS-CoV* variation. (A) PhyML tree of full-length genome sequences of 15 distinct MERS coronavirus variants based on analysis of nucleotide sequence diversity across the genome. Four major *MERS-CoV* clusters are indicated (A, B1, B2, C). (B) The number of nucleotide positions with variations over 15 representative *MERS-CoV* genomes (Supplementary Table 1) was plotted over 1000 nucleotide windows. A schematic diagram of the *MERS-CoV* genome is depicted below the graph, and four fragments with the highest number of single nucleotide polymorphisms (SNPs) are indicated with black boxes. The dotted line indicates the average number of SNPs per 1000 nt window added with 1x standard deviation. In red, nucleotide positions displaying considerable phylogenetic information regarding four identified *MERS-CoV* variant clusters and the red box indicates the 615 bp fragment of the here-described *MERS-CoV* variant typing assay. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

In a subsequent analysis all identified SNPs were inspected visually and regions containing SNPs with phylogenetic information regarding the previously identified four clusters of viruses were identified ([Fig. 1](#fig0005){ref-type="fig"}A). The S2 domain of the spike protein contains a number of these mutations ([Fig. 1](#fig0005){ref-type="fig"}B). A fragment of 615 bp, containing three of these SNPs, provided a phylogenetic tree similar to the one obtained upon full-genome analysis regarding the previously identified four *MERS-CoV* clusters ([Fig. 2](#fig0010){ref-type="fig"} ), whereas other *MERS-CoV* genome regions did not provide similar results. As observed for the full-length genomes, human, and camel *MERS-CoV* genomes shared \>99% nucleotide identity across the 615 bp S2 domain fragment. *MERS-CoV* genomes that were released recently and not taken along in the variation analysis were typed using the 615 bp S2 domain and clustered similar to their phylogenetic positions as upon full genome analysis ([Fig. 2](#fig0010){ref-type="fig"} and [Table 1](#tbl0005){ref-type="table"}), thereby validating the assay.Fig. 2Phylogenetic analysis of human and camel *MERS-CoVs* using the *MERS-CoV* variant typing assay. A PhyML tree was generated from a spike S2 domain genome fragment corresponding to nt 23781--24395 of *MERS-CoV* EMC genome (accession number [JX869059](ncbi-n:JX869059){#intr0005}) for known *MERS-CoV* genomes ([Table 1](#tbl0005){ref-type="table"}) and the first two Dutch *MERS-CoV* patients (boxed). In red are newly identified camel sequences from a slaughterhouse in Qatar. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

A sequencing RT-PCR targeting the identified genome fragment was developed and optimized using RNA isolated from cell culture-derived *MERS-CoV*. In limiting dilution experiments, the *MERS-CoV* variant typing assay amplified the 615 bp fragment down to a cycle treshold value of ∼35 as determined by diagnostic upE real time PCR assays [@bib0085], [@bib0090]. The *MERS-CoV* variant typing assay was used to type RT-PCR positive nose swabs from the first two human Dutch *MERS-CoV* cases in 2014. The results showed grouping consistent with previous findings based on long sequence fragments [@bib0095] ([Fig. 2](#fig0010){ref-type="fig"}). In addition, the *MERS-CoV* variant typing assay was performed on camel samples from a slaughterhouse in Qatar [@bib0065] and sequences for 14 *MERS-CoV* positive animals with cycle threshold values ranging from 12.9 to 32.2 as determined by UpE real time RT-PCR [@bib0085], [@bib0090] were obtained ([Fig. 2](#fig0010){ref-type="fig"}). Five different camel *MERS-CoV* variants in clusters B1 and B2 were detected, without the need for full genome sequencing.

5. Discussion {#sec0040}
=============

Phylogenetic analysis of representative *MERS-CoV* full-length genomes indicated that four regions in the *MERS-CoV* genome exist with a substantially higher nucleotide variation across genomes. However, phylogenetic analysis of these genome regions separately did not provide reliable phylogenetic information, in contrast to an analysis of the concatenated fragments [@bib0025], [@bib0060], [@bib0095]. Subsequent analyses revealed a region in the open reading frame that encodes the spike protein with a number of positions in which nucleotide variation occurs between *MERS-CoV* variants with a strong phylogenetic signal regarding previously identified clusters of viruses based on full-length *MERS-CoV* genomes. The here-described *MERS-CoV* variant typing assay based on a 615 bp spike fragment provides a crude indication of the *MERS-CoV* variant under study on the basis of four identified clusters of *MERS-CoV* variants, exemplified by *MERS-CoV* Qatar_3\_2014, England/Qatar_2012, EMC_2012, and Egypt_Camel_NRCE-HKU205_2014. In silico, the assay accurately typed all currently known *MERS-CoVs* for which full-length genomes are available, including the recently released Florida/USA_2\_KSA_2014 and Indiana/USA-1_KSA_2014 strains. This was confirmed by typing of samples available in our laboratory from the first two Dutch *MERS-CoV* cases that phylogenetically grouped with Indiana/USA-1_KSA_2014 and other viruses in cluster I [@bib0095] and from camels from a slaughterhouse in Doha, Qatar [@bib0065]. The observed detection limit of a cycle treshold value of ∼35 allows variant typing in clinical samples obtained from humans and animals with relatively low viral loads. It enables inclusion of samples in phylogenetic analysis that would not have been included when only full length genomes would have been accepted.

This *MERS-CoV* variant typing assay, targeting a part of the *MERS-CoV* spike gene, is a relatively simple RT-PCR sequencing assay that could be performed more widely as initial screening assay in laboratories with basic sequencing capacity. It provides accurate crude *MERS-CoV* type information, applicable in monitoring viral variants in real time. New variants identified through this initial screening could then be sent to a reference laboratory for further characterization. The continued occurrence of transmission between humans in health care and family settings is an ongoing concern as stated by the World Health Organization ([http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_27_March_2014.pdf?ua=1](http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_27_March_2014.pdf%3Fua=1){#intr0315}), although the outbreaks appear to be self‐limiting or extinguishable with rigorous implementation of appropriate infection control guidelines at present. However, as the primary route of transmission to humans is uninterrupted, human-to-human transmissions will continue to occur. The data obtained from the *MERS-CoV* variant typing assay would aid in informing the most effective international preparedness and response, allowing ad hoc risk assessment and implementation of containment strategies if necessary.
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